Moderna’s mRNA‑1283 cuts COVID‑19 risk 35.9% vs Pfizer in older US veterans
A retrospective VA cohort study of veterans aged 65 and older found that Moderna’s next‑generation vaccine mRNA‑1283 reduced medically attended COVID‑19 by 35.9% and COVID‑19‑related hospitalizations by 47.0% compared with Pfizer‑BioNTech’s BNT162b2. The analysis covered 294,499 matched participants vaccinated between Aug. 27 2025 and Jan. 31 2026 and followed them for up to 150 days. Moderna supported the study but did not collect or analyze the data.
Why it matters
The company says the findings could steer seasonal vaccine selection toward mRNA‑1283 for high‑risk older adults, potentially boosting Moderna’s market share in the senior segment. Investors should watch whether the durability signal translates into higher uptake and revenue growth.
Key facts
- 1The study reported a 35.9% lower risk of medically attended COVID‑19 for mRNA‑1283 versus BNT162b2 (95% CrI 20.4‑49.7%). pharmacytimes.com
- 2COVID‑19‑associated hospitalization risk was 47.0% lower with mRNA‑1283 (95% CrI 5.4‑74.8%). pharmacytimes.com
- 3A total of 294,499 veterans were included in the matched analysis. pharmacytimes.com
- 455,349 participants received mRNA‑1283 and 239,150 received BNT162b2. pharmacytimes.com
- 5The absolute risk difference was 10 fewer medically attended COVID‑19 events per 10,000 vaccinated individuals. pharmacytimes.com
- 6Hospitalization absolute difference was 2.2 fewer hospitalizations per 10,000 vaccinated individuals. drugtopics.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.